Abstract 3664: Pioglitazone Increases Plasma Adiponectin Concentration and Decreases Coronary Plaque Necrotic Core: Intravascular Ultrasound Virtual Histology Study
Background: Recent studies suggest the effectiveness of pioglitazone (PIO) in preventing the cardiovascular events. But, whether PIO is effective in stabilizing the coronary plaque remains unknown.
Methods: Study subjects were 36 patients who underwent percutaneous coronary intervention (PCI). PCI non-target lesions with significant stenosis (69 lesions) were evaluated with Intravascular Ultrasound Virtual Histology (VH-IVUS) and the ratio of each plaque component (FI:Fibrous, FF:Fibro-Fatty, DC:Dense-Calcium, NC: Necrotic-Core) to the total plaque volume was obtained. Eight patients (20 lesions) were administered PIO for the treatment of diabetes mellitus (TZD group), and other 28 patients (49 lesions) without PIO served as control (non-TZD group). At 6 month follow-up, VH-IVUS was fulfilled in the same lesions and evaluated the change of each component. Plasma adiponectin (AdN) levels were measured before PCI and 6 month after treatment.
Results: Increase in AdN level of TZD group was larger than that of non-TZD group (6.29±5.43 μg/ml vs -0.42±3.9 μg/ml, p=0.0006). Decrease in %NC of TZD group was greater than that of non-TZD group (4.4±6.0 % vs -1.8±9.5 %, p=0.009). Moreover, there was a significant negative correlation between the change in AdN level and %increase in NC (p<0.0001, r=-0.603, Figure⇓). Also, significant correlations between the change in AdN level and %increase in other plaque components were observed (FI:p=0.0029, r=0.354 FF:p=0.0003, r=0.422, DC:p=0.0008, r=-0.396 respectively).
Conclusion: Treatment with pioglitazone increases plasma adiponectin level and decreases lipid-necrotic component, may lead to stabilize the coronary plaque.